Herantis Pharma Plc announced Results of proof-of-concept study demonstrating successful nanoforming of HER-096 into nanoparticles and further exploration the applicability of Nanoform's technology in the development of an oral dosage form based on HER-096 nanoparticles. Herantis has previously shown that HER-096 penetrates the blood brain barrier and enters the brain in therapeutic concentrations in healthy rats following subcutaneous administration. Subcutaneous administration will be used in Herantis' HER-096 first-in-human clinical study that is expected to commence in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 EUR | +2.10% | +1.74% | -7.30% |
Mar. 06 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 06 | Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024 |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.30% | 31.42M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- HRTIS Stock
- News Herantis Pharma Oyj
- Herantis Pharma Plc Announces Successful HER-096 Initial Results with Nanoform Technology